$PMCB Is A Four Bagger
It has been over a year since we have written about PharmaCyte Biotech (OTCQB – PMCB), formerly Nuvilex we believe that these shares are grossly undervalued in light of the Company’s increasingly growing profile in the medical community due to its current and future activity and visibility on the clinical trial front. In fact, one could argue that PMCB is in better positioning now than a year ago, when it traded much higher.
Seven Reasons Why We Believe PMCB is a Four Bagger
PMCB owns exclusive rights to a technology that could emerge as the first universal therapy and treatment of choice for multiple cancers and diabetes, potentially worth billions in annual sales down the road.
Favorable legacy and updated results from early-mid-stage pancreatic cancer clinical trials will be followed by the commencement of a Phase 2b clinical trial in 2H15.
The high profile and coveted Orphan Drug designation was granted by the FDA in December, 2014 to PMCB’s pancreatic cancer treatment.
Preclinical trials for abdominal cancers using the Company’s platform technology were designed, in part, by the leading authority on pancreatic cancer, Dr. Daniel Von Hoff, and conducted by America’s leading Contract Research Organization that specializes in oncology. This substantially raises the PMCB profile and could result in future, fast-tracked trials.
A series of steps are in progress that will lead toward diabetes clinical trials, which, in turn, represent a substantial market opportunity.
Management is actively engaged in pursuing the use of compounds from the Cannabis plant (known as “cannabinoids”) in combination with its Cell-in-a-Box® platform technology to treat deadly cancers where there are no substantially effective treatments on the market.
With multiple shots on goal we believe that PMCB’s stock is overlooked and grossly undervalued, relative to its peer group, as outlined in our report.
